|
pubmed:abstractText |
The role of genetic polymorphisms and genetic testing in guiding warfarin dosing is discussed, as are the selection and monitoring of anticoagulant therapy for obese patients, patients with severe renal impairment, and patients with heparin-induced thrombocytopenia (HIT); case studies are used to illustrate each topic.
|
